Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study
Identifieur interne : 000B36 ( Istex/Curation ); précédent : 000B35; suivant : 000B37Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study
Auteurs : Björn Holmberg [Suède] ; Jan-Ove Johansson [Suède] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Niall P. Quinn [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Adriana Cardozo [Espagne] ; Nil Dizdar [Suède] ; Olivier Rascol [France] ; Tarik Slaoui [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-06-15.
English descriptors
Abstract
The objective of this study was to investigate tolerability and possible neurotrophic effects of growth hormone (GH) in treatment of multiple system atrophy (MSA). In this double‐blind pilot study, MSA patients were randomized to recombinant human growth hormone (r‐hGH, n = 22), 1 mg every second day (6 months) followed by alternating daily injections of 1 mg and 0.5 mg (6 months), or matched placebo (n = 21). Safety analysis demonstrated no obvious between‐group differences. In both groups, there was progressive worsening of Unified Parkinson's Disease Rating Scale total score, which tended to be less in r‐hGH‐treated patients (12.9% at 6 months, 25.3% at 12 months) than in placebo (17.0% and 35.7%). Similarly, there was a trend to less worsening in Unified MSA Rating Scale total score with r‐hGH (13.2% and 21.2%) than with placebo (21.1% and 36.5%). Cardiovascular reflex autonomic testing also tended to show less deterioration with r‐hGH than with placebo at 12 months. However, 95% CI did not indicate treatment differences for any efficacy measures. In conclusion, r‐hGH administration in MSA patients for up to 1 year appears safe and might influence disease symptoms, signs and, possibly, progression. The results support further studies utilizing higher doses in more patients. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21501
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B36
Links to Exploration step
ISTEX:42A6C3E12B4F24D2ED689E59DB9B5A6693D388C2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study</title><author><name sortKey="Holmberg, Bjorn" sort="Holmberg, Bjorn" uniqKey="Holmberg B" first="Björn" last="Holmberg">Björn Holmberg</name><affiliation wicri:level="1"><mods:affiliation>Movement Disorders Unit, Sahlgrenska University Hospital, Göteborg University, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Movement Disorders Unit, Sahlgrenska University Hospital, Göteborg University</wicri:regionArea></affiliation></author><author><name sortKey="Johansson, Jan Ve" sort="Johansson, Jan Ve" uniqKey="Johansson J" first="Jan-Ove" last="Johansson">Jan-Ove Johansson</name><affiliation wicri:level="1"><mods:affiliation>Movement Disorders Unit, Sahlgrenska University Hospital, Göteborg University, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Movement Disorders Unit, Sahlgrenska University Hospital, Göteborg University</wicri:regionArea></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital Innsbruck, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital Innsbruck, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Wenning, Gregor" sort="Wenning, Gregor" uniqKey="Wenning G" first="Gregor" last="Wenning">Gregor Wenning</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital Innsbruck, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital Innsbruck, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name><affiliation wicri:level="1"><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, UK</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London</wicri:regionArea></affiliation></author><author><name sortKey="Mathias, Chris" sort="Mathias, Chris" uniqKey="Mathias C" first="Chris" last="Mathias">Chris Mathias</name><affiliation wicri:level="1"><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, UK</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London</wicri:regionArea></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation wicri:level="1"><mods:affiliation>Hospital Clinic de Barcelona, Servicio de Neurologia, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clinic de Barcelona, Servicio de Neurologia, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Cardozo, Adriana" sort="Cardozo, Adriana" uniqKey="Cardozo A" first="Adriana" last="Cardozo">Adriana Cardozo</name><affiliation wicri:level="1"><mods:affiliation>Hospital Clinic de Barcelona, Servicio de Neurologia, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clinic de Barcelona, Servicio de Neurologia, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Dizdar, Nil" sort="Dizdar, Nil" uniqKey="Dizdar N" first="Nil" last="Dizdar">Nil Dizdar</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Linköping University Hospital, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Neurology, Linköping University Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology, Clinical Investigation Center, Hôpital Purpan, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pharmacology, Clinical Investigation Center, Hôpital Purpan, Toulouse</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurosciences, Clinical Investigation Center, Hôpital Purpan, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurosciences, Clinical Investigation Center, Hôpital Purpan, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Slaoui, Tarik" sort="Slaoui, Tarik" uniqKey="Slaoui T" first="Tarik" last="Slaoui">Tarik Slaoui</name><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology, Clinical Investigation Center, Hôpital Purpan, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pharmacology, Clinical Investigation Center, Hôpital Purpan, Toulouse</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurosciences, Clinical Investigation Center, Hôpital Purpan, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurosciences, Clinical Investigation Center, Hôpital Purpan, Toulouse</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:42A6C3E12B4F24D2ED689E59DB9B5A6693D388C2</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21501</idno><idno type="url">https://api.istex.fr/document/42A6C3E12B4F24D2ED689E59DB9B5A6693D388C2/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B36</idno><idno type="wicri:Area/Istex/Curation">000B36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study</title><author><name sortKey="Holmberg, Bjorn" sort="Holmberg, Bjorn" uniqKey="Holmberg B" first="Björn" last="Holmberg">Björn Holmberg</name><affiliation wicri:level="1"><mods:affiliation>Movement Disorders Unit, Sahlgrenska University Hospital, Göteborg University, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Movement Disorders Unit, Sahlgrenska University Hospital, Göteborg University</wicri:regionArea></affiliation></author><author><name sortKey="Johansson, Jan Ve" sort="Johansson, Jan Ve" uniqKey="Johansson J" first="Jan-Ove" last="Johansson">Jan-Ove Johansson</name><affiliation wicri:level="1"><mods:affiliation>Movement Disorders Unit, Sahlgrenska University Hospital, Göteborg University, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Movement Disorders Unit, Sahlgrenska University Hospital, Göteborg University</wicri:regionArea></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital Innsbruck, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital Innsbruck, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Wenning, Gregor" sort="Wenning, Gregor" uniqKey="Wenning G" first="Gregor" last="Wenning">Gregor Wenning</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital Innsbruck, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital Innsbruck, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name><affiliation wicri:level="1"><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, UK</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London</wicri:regionArea></affiliation></author><author><name sortKey="Mathias, Chris" sort="Mathias, Chris" uniqKey="Mathias C" first="Chris" last="Mathias">Chris Mathias</name><affiliation wicri:level="1"><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, UK</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London</wicri:regionArea></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation wicri:level="1"><mods:affiliation>Hospital Clinic de Barcelona, Servicio de Neurologia, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clinic de Barcelona, Servicio de Neurologia, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Cardozo, Adriana" sort="Cardozo, Adriana" uniqKey="Cardozo A" first="Adriana" last="Cardozo">Adriana Cardozo</name><affiliation wicri:level="1"><mods:affiliation>Hospital Clinic de Barcelona, Servicio de Neurologia, Barcelona, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clinic de Barcelona, Servicio de Neurologia, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Dizdar, Nil" sort="Dizdar, Nil" uniqKey="Dizdar N" first="Nil" last="Dizdar">Nil Dizdar</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Linköping University Hospital, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Neurology, Linköping University Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology, Clinical Investigation Center, Hôpital Purpan, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pharmacology, Clinical Investigation Center, Hôpital Purpan, Toulouse</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurosciences, Clinical Investigation Center, Hôpital Purpan, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurosciences, Clinical Investigation Center, Hôpital Purpan, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Slaoui, Tarik" sort="Slaoui, Tarik" uniqKey="Slaoui T" first="Tarik" last="Slaoui">Tarik Slaoui</name><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology, Clinical Investigation Center, Hôpital Purpan, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pharmacology, Clinical Investigation Center, Hôpital Purpan, Toulouse</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurosciences, Clinical Investigation Center, Hôpital Purpan, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurosciences, Clinical Investigation Center, Hôpital Purpan, Toulouse</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-06-15">2007-06-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1138">1138</biblScope><biblScope unit="page" to="1144">1144</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">42A6C3E12B4F24D2ED689E59DB9B5A6693D388C2</idno><idno type="DOI">10.1002/mds.21501</idno><idno type="ArticleID">MDS21501</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>UMSARS</term><term>UPDRS</term><term>autonomic testing</term><term>growth hormone treatment</term><term>multiple system atrophy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to investigate tolerability and possible neurotrophic effects of growth hormone (GH) in treatment of multiple system atrophy (MSA). In this double‐blind pilot study, MSA patients were randomized to recombinant human growth hormone (r‐hGH, n = 22), 1 mg every second day (6 months) followed by alternating daily injections of 1 mg and 0.5 mg (6 months), or matched placebo (n = 21). Safety analysis demonstrated no obvious between‐group differences. In both groups, there was progressive worsening of Unified Parkinson's Disease Rating Scale total score, which tended to be less in r‐hGH‐treated patients (12.9% at 6 months, 25.3% at 12 months) than in placebo (17.0% and 35.7%). Similarly, there was a trend to less worsening in Unified MSA Rating Scale total score with r‐hGH (13.2% and 21.2%) than with placebo (21.1% and 36.5%). Cardiovascular reflex autonomic testing also tended to show less deterioration with r‐hGH than with placebo at 12 months. However, 95% CI did not indicate treatment differences for any efficacy measures. In conclusion, r‐hGH administration in MSA patients for up to 1 year appears safe and might influence disease symptoms, signs and, possibly, progression. The results support further studies utilizing higher doses in more patients. © 2007 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000B36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:42A6C3E12B4F24D2ED689E59DB9B5A6693D388C2
|texte= Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study
}}
| This area was generated with Dilib version V0.6.23. |  |